10x Genomics And Harvard University Resolve Patent Lawsuit With Vizgen In US Court Amidst Trial
10x Genomics And Harvard University Resolve Patent Lawsuit With Vizgen In US Court Amidst Trial
Strap – Representatives of both groups were pleased with the resolution
10x Genomics Inc and Harvard University have agreed to resolve a patent lawsuit with Vizgen Inc.
Earlier, they approached the US District Court for the District of Delaware accusing Vizgen of infringing patents related to gene analysis.
However, Vizgen counter-sued both for allegedly breaking a contract with the National Institutes of Health by monopolizing their technology.
10x Genomics and Harvard informed the court that they would dismiss the case with prejudice (meaning, the claims and counterclaims cannot be refiled).
In 2022, 10x Genomics sued for allegedly infringing patents covering its Xenium In Situ gene-analysis platform. 10x Genomics licenses the patents from the university, also a plaintiff.
10x Genomics and Harvard demanded $9.2 million in damages, while Vizgen sought between $91 million and $374 million.
In a related patent lawsuit, antitrust allegations against 10x Genomics and Harvard are ongoing from life sciences company Bruker.
